pcmr12096-sup-0001-FigureS1.epsimage/eps3735KFigure S1. CpG islands within gene promoter regions are analyzed for validation of gene methylation status.
pcmr12096-sup-0002-FigureS2.epsimage/eps18295KFigure S2. Promoter methylation status of HOXA9, MAPK13, CDH11, PLEKHG6, PPP1R3C, and CLDN11 in metastatic melanoma samples.
pcmr12096-sup-0003-FigureS3.epsimage/eps4133KFigure S3. Restoration of MAPK13 expression in melanoma cells with MAPK13 promoter methylation attenuates proliferation, long-term growth curves.
pcmr12096-sup-0004-FigureS4.epsimage/eps2451KFigure S4. Depletion of MAPK13 does not prevent cell cycle arrest induced by BRAFV600E in human fibroblasts.

Table S1. (A) Fresh-frozen biopsies of nevus, primary cutaneous melanoma, and melanoma metastases; (B) Early passage melanoma cell lines, isolated from metastatic lesions of patients treated at Leiden University Medical Center.

Table S2. (A) Bisulfite primers; (B) qPCR primers; (C) BRAF and NRAS sequencing primers.

Table S3. (A) List of the 106 unique genes (P < 0.05 and average β-value difference > 0.20) identified as hypermethylated in primary melanoma. (B) List of the 44 unique genes (P < 0.05 and average β-value difference > −0.20) identified as hypomethylated in primary melanoma.

pcmr12096-sup-0005-FigureLegends.docWord document31K 

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.